Regen BioPharma Files Patent Application on Personalized Checkpoint Inhibitor Cancer Immunotherapy.  Company Intends to Utilize NR2F6 Gene-Silenced Immune Cells to Amplify Body’s Own Anti-Tumor Defenses.

Leave a Reply

Your email address will not be published.